IMS, SDI request a rehearing on NH data ban

Share this article:
Supreme Court shrugs at NH data ban
Supreme Court shrugs at NH data ban

A motion to challenge New Hampshire's law banning the commercial use of prescriber-identifiable data has been filed by research companies IMS Health and SDI. The move represents round three in the battle to repeal the ban, a violation of free commercial speech, according to the companies involved.

After a US district court sided with the two companies and awarded an injunction against the ban in May 2007, the US Court of Appeals for the First Circuit overturned that decision in November. SDI and IMS Health are arguing that a ban on prescriber-identifiable data – information that identifies physicians and other healthcare providers for marketing purposes – constitutes a violation of the First Amendment. 

“We strongly believe the First Amendment protects the full dissemination of prescriber-identifiable data, which is vital to efforts to improve the quality, efficiency and safety of our healthcare system. Further, we agree with prior decisions that without these data the potential exists to compromise patient care,” the companies said in a joint statement that also announced “a strong basis for a rehearing.”

SDI and IMS Health's request for a rehearing will be closely monitored by other research firms, and may instigate challenges to similar bans in Vermont and Maine, and pending bans in a dozen other states. The Vermont ban, unlike the New Hampshire law, allows a prescriber to "opt in," or give consent to the use of his identity. In Maine, a prescriber can "opt out" of having his identity used for marketing purposes.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...